Novo Nordisk Should Have Studied Insulin Icodec Twice-Weekly Dosing, US Panel Says

FDA had recommended studying a twice-weekly dose, but Novo declined because it would add complexity to treatment for type 1 diabetes. However, the firm’s proposed strategy for reducing hypoglycemia risk with once-weekly insulin icodec would create its own complexity, panel said.